5 Strong Buy Stocks with High Upside According to Analysts

4. Boston Scientific Corporation (NYSE:BSX)

Upside Potential: 62.55%

On July 8, Needham analyst Mike Matson lowered the firm’s price target on Boston Scientific Corporation (NYSE:BSX) to $57 from $77 while maintaining a Buy rating on the shares. The adjustment followed management commentary indicating that sales of the company’s WATCHMAN device have slowed, with expectations for sequentially flat sales during the second and third quarters. According to Needham, management attributed part of the slowdown to workflow-related challenges, while the firm believes recent clinical trial developments and reimbursement dynamics may also be affecting growth. Despite these near-term pressures, Needham continues to view Boston Scientific favorably, given its broader portfolio strength and long-term growth opportunities.

Earlier, on July 6, Evercore ISI lowered its price target on Boston Scientific Corporation (NYSE:BSX) to $65 from $78 while reiterating an Outperform rating. In its second-quarter preview of the medical technology sector, the firm highlighted generally healthy procedure volumes and capital spending trends across healthcare markets. While acknowledging some product-specific challenges, Evercore continues to view Boston Scientific as a well-positioned industry leader capable of benefiting from favorable long-term healthcare and medical device demand trends.

Founded in 1979 and headquartered in Marlborough, Massachusetts, Boston Scientific Corporation (NYSE:BSX) is a global medical technology company that develops, manufactures, and markets minimally invasive medical devices. Although analysts have reduced their price targets, Boston Scientific’s diversified product portfolio, strong position in multiple high-growth medical markets, and continued Buy and Outperform ratings support a constructive long-term investment outlook, making it one of the strong buy stocks with high upside according to analysts.